Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 04 10:17AM ET
0.8008
Dollar change
-0.0249
Percentage change
-3.01
%
Index- P/E- EPS (ttm)-1.35 Insider Own14.94% Shs Outstand72.78M Perf Week47.22%
Market Cap58.42M Forward P/E- EPS next Y-1.05 Insider Trans-0.06% Shs Float62.06M Perf Month38.08%
Income-98.57M PEG- EPS next Q-0.31 Inst Own50.34% Short Float1.39% Perf Quarter46.34%
Sales7.00M P/S8.35 EPS this Y12.44% Inst Trans4.51% Short Ratio1.28 Perf Half Y0.41%
Book/sh2.07 P/B0.39 EPS next Y14.62% ROA-44.47% Short Interest0.87M Perf Year-20.72%
Cash/sh2.25 P/C0.36 EPS next 5Y- ROE-51.48% 52W Range0.52 - 1.13 Perf YTD-15.48%
Dividend Est.- P/FCF- EPS past 5Y9.06% ROI-60.68% 52W High-29.45% Beta0.20
Dividend TTM- Quick Ratio9.58 Sales past 5Y0.00% Gross Margin84.59% 52W Low53.93% ATR (14)0.05
Dividend Ex-Date- Current Ratio9.58 EPS Y/Y TTM-18.69% Oper. Margin-1422.01% RSI (14)72.61 Volatility11.90% 6.08%
Employees58 Debt/Eq0.12 Sales Y/Y TTM- Profit Margin-1408.11% Recom2.33 Target Price2.50
Option/ShortYes / Yes LT Debt/Eq0.08 EPS Q/Q11.83% Payout- Rel Volume0.41 Prev Close0.83
Sales Surprise-100.00% EPS Surprise6.16% Sales Q/Q- EarningsAug 13 AMC Avg Volume676.85K Price0.80
SMA2030.85% SMA5030.73% SMA2005.04% Trades Volume45,257 Change-3.01%
Date Action Analyst Rating Change Price Target Change
Aug-11-23Downgrade Wells Fargo Overweight → Equal Weight $4
Mar-16-23Downgrade William Blair Outperform → Mkt Perform
Dec-08-21Initiated Wells Fargo Overweight $19
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Oct-01-24 04:52AM
Sep-30-24 08:30AM
Sep-04-24 04:01PM
Aug-14-24 11:13AM
Aug-13-24 04:02PM
04:01PM Loading…
Jul-10-24 04:01PM
Jun-07-24 05:59PM
May-29-24 04:01PM
May-09-24 10:57PM
04:01PM
May-06-24 04:05PM
Apr-08-24 05:38PM
04:01PM
Mar-27-24 04:30PM
Mar-16-24 06:56AM
09:54PM Loading…
Mar-14-24 09:54PM
04:01PM
Mar-08-24 04:05PM
Feb-28-24 04:01PM
Feb-26-24 06:30PM
Feb-25-24 02:12PM
Feb-02-24 05:37AM
Dec-18-23 08:51AM
Nov-21-23 04:01PM
Nov-13-23 04:01PM
Nov-03-23 04:03PM
Oct-24-23 12:30PM
Oct-23-23 10:08AM
Oct-09-23 05:56PM
Oct-04-23 09:32AM
04:10PM Loading…
Oct-03-23 04:10PM
Sep-20-23 06:30PM
Aug-31-23 04:01PM
Aug-10-23 04:01PM
Aug-04-23 04:03PM
Jul-07-23 04:01PM
Jun-09-23 04:01PM
May-31-23 07:00AM
May-11-23 04:01PM
Apr-05-23 04:01PM
Mar-14-23 04:01PM
Mar-13-23 07:00AM
Mar-06-23 07:00AM
Mar-03-23 06:17PM
Mar-01-23 04:01PM
Feb-06-23 04:01PM
11:44AM
Jan-26-23 06:44AM
Jan-13-23 04:01PM
Jan-06-23 07:04AM
Jan-04-23 04:01PM
Dec-07-22 04:01PM
Nov-14-22 07:00AM
Nov-11-22 04:01PM
Nov-10-22 04:01PM
Nov-09-22 04:01PM
Nov-03-22 10:00AM
Oct-14-22 07:00AM
Oct-06-22 04:01PM
Oct-03-22 04:01PM
Sep-29-22 04:05PM
Sep-02-22 04:30PM
Sep-01-22 07:00AM
Aug-30-22 12:10PM
Aug-11-22 04:01PM
Aug-03-22 04:30PM
Jul-18-22 09:55AM
Jul-11-22 04:30PM
Jul-08-22 02:42PM
Jul-07-22 04:30PM
Jul-06-22 04:30PM
Jun-30-22 01:08PM
09:55AM
Jun-28-22 03:57PM
11:58AM
10:23AM
09:58AM
Jun-27-22 09:31PM
04:01PM
11:46AM
Jun-10-22 09:35AM
Jun-03-22 04:30PM
Jun-01-22 06:15AM
May-23-22 09:55AM
09:35AM
May-12-22 04:01PM
May-11-22 09:32AM
08:59AM
May-10-22 08:38AM
May-05-22 04:30PM
May-04-22 03:57PM
05:57AM
May-03-22 04:01PM
Apr-15-22 04:05PM
Apr-05-22 07:00AM
Mar-24-22 11:03AM
Mar-23-22 04:58PM
Mar-18-22 12:42PM
Mar-17-22 04:01PM
Mar-02-22 07:00AM
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schiller Mark C.Chief Legal OfficerJul 02 '24Sale0.586,6883,87933,007Jul 26 05:41 PM